Molecular status [polymerase-ɛ (POLE) mutation, mismatch repair (MMR) status and p53 mutation] has also emerged as an invaluable prognostic and predictive biomarker in endometrial cancer and has been incorporated in the new FIGO 2023 stage and ESGO/ESTRO/ESP risk classification groups. This evidence concerns the gene TP53 and endometrial cancer.